Gavocabtagene autoleucel

DB17367InvestigationalCell transplant therapies

Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression,...

Mechanism: Pharmacologically active on Mesothelin
Curator reviewed
Also known as: Gavo-cel
Code names: TC-210

Resolves to

Compound

UNIINP6CFH3G8H

Targets

Q13421MSLN

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gavocabtagene autoleucel, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account